BerGenBio

Selective AXL inhibitors

Home  /  Media Centre  /  Presentations

SITC 2019, Matthew Krebs et al

Share This Presentation

8 November 2019, Maryland, USA

Oral presentation in High Impact Clinical Trials:

A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis

Share This Presentation

Latest News

News

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

News

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.